GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Net Cash per Share

ALX Oncology Holdings (ALX Oncology Holdings) Net Cash per Share : $2.60 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is ALX Oncology Holdings Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). ALX Oncology Holdings's Net Cash per Share for the quarter that ended in Dec. 2023 was $2.60.

The historical rank and industry rank for ALX Oncology Holdings's Net Cash per Share or its related term are showing as below:

ALXO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.06   Med: 4.13   Max: 8.03
Current: 6.23

During the past 6 years, the highest Price-to-Net-Cash Ratio of ALX Oncology Holdings was 8.03. The lowest was 2.06. And the median was 4.13.

ALXO's Price-to-Net-Cash is ranked worse than
64.28% of 865 companies
in the Biotechnology industry
Industry Median: 4.14 vs ALXO: 6.23

ALX Oncology Holdings Net Cash per Share Historical Data

The historical data trend for ALX Oncology Holdings's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings Net Cash per Share Chart

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial -0.06 10.74 8.54 5.46 2.60

ALX Oncology Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.46 4.65 4.38 3.37 2.60

Competitive Comparison of ALX Oncology Holdings's Net Cash per Share

For the Biotechnology subindustry, ALX Oncology Holdings's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ALX Oncology Holdings's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's Price-to-Net-Cash falls into.



ALX Oncology Holdings Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

ALX Oncology Holdings's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(182.736-52.841-0)/49.952
=2.60

ALX Oncology Holdings's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(182.736-52.841-0)/49.952
=2.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ALX Oncology Holdings  (NAS:ALXO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


ALX Oncology Holdings Net Cash per Share Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ALX Oncology Holdings (ALX Oncology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Executives
Shelly Pinto officer: VP, Finance and CAO 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia officer: Chief Financial Officer ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Sophia Randolph officer: Chief Medical Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons director, officer: President and CEO C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas director C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Jason Lettmann director, 10 percent owner C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lsv Associates, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Goodman Corey S director, 10 percent owner, other: Executive Chairman 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Rekha Hemrajani director 3928 POINT EDEN WAY, HAYWARD CA 94545
Venbio Global Strategic Fund, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Steffen Pietzke officer: VP Fin & Chief Acct Officer C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538

ALX Oncology Holdings (ALX Oncology Holdings) Headlines

From GuruFocus

ALX Oncology Announces Proposed Public Offering

By Marketwired 10-04-2023

ALX Oncology Realigns Executive Leadership Team

By Marketwired 09-06-2023